Background {#Sec1}
==========

Metabolic syndrome is a cluster of factors that substantially increase the risk for atherosclerotic cardiovascular disease and diabetes \[[@CR1], [@CR2]\]. The estimated prevalence of metabolic syndrome found in most industrialized countries is 20-30 % \[[@CR3]--[@CR5]\]. For the United States, the National Health and Nutrition Examination Survey (NHANES) age adjusted data from 2003 to 2006 estimated that 34 % of Americans had metabolic syndrome, representing a 10 % increase over the previous 10--15 years \[[@CR6]\]. The increased prevalence of metabolic syndrome is a worldwide public health issue, driven primarily by higher rates of obesity and an aging population \[[@CR3], [@CR4]\]. These observations highlight the urgent need for effective strategies to treat the underlying causes of metabolic syndrome, including weight loss, increased physical activity, and management of factors responsible for elevated cardiometabolic risk.

Recently defined criteria used to diagnose metabolic syndrome include abdominal obesity (waist circumference), dyslipidemia (reduced levels of high-density lipoprotein cholesterol \[HDL-C\] and high triglycerides), elevated blood pressure, and elevated fasting glucose \[[@CR7]\]. Several national and international organizations have provided guidance for the management of metabolic syndrome and associated cardiovascular risk and for those patients with dyslipidemia \[[@CR1], [@CR8]--[@CR12]\] Many international guidelines recommend specific treatment targets for low-density lipoprotein cholesterol (LDL-C), non-HDL-C, and apolipoprotein (apo) B levels based on cardiovascular risk; however the 2013 American College of Cardiology (ACC)/American Heart Association (AHA) guidelines focus on the identification of patient groups most likely to benefit from treatment with high-intensity statins that will result in LDL-C lowering by ≥50 % or by 30 to \<50 %, respectively \[[@CR12]\]. Obesity and insulin resistance modulate the normal pattern of lipid metabolism which promotes the development of atherogenic dyslipidemia, including higher levels of triglyceride-rich very-low density lipoprotein (VLDL), greater numbers of apo B-containing small-dense LDL particles, and increased clearance of circulating HDL \[[@CR13]\]. These metabolic changes may potentially influence the efficacy of lipid-altering drugs, and it is therefore important to determine the effects of metabolic syndrome factors and insulin resistance on treatment.

The Vytorin in Metabolic Syndrome (VYMET) study was conducted in patients with metabolic syndrome, hypercholesterolemia, and either moderately high or high coronary heart disease (CHD) risk. Primary analysis of this study showed that after 6 weeks of treatment, ezetimibe/simvastatin produced significantly greater improvements in LDL-C and other key lipid parameters than atorvastatin at the doses compared \[[@CR14]\]. The objective of this current *post hoc* analysis was to evaluate the efficacy of treatment in the presence or absence of specific metabolic syndrome factors and insulin resistance tertiles.

Methods {#Sec2}
=======

Trial design {#Sec3}
------------

This *post hoc* analysis evaluated data from the previously reported multicenter, randomized, double-blind, 5-arm, parallel-group VYMET study (NCT00409773; protocol number 107) that was designed to assess the lipid-altering efficacy of ezetimibe/simvastatin and atorvastatin in subjects with metabolic syndrome and elevated cardiovascular risk \[[@CR14]\]. The protocol was approved by the institutional review board or ethics committee of each participating study site, and all patients provided written informed consent.

Subjects and therapy {#Sec4}
--------------------

Details of the study have been described previously \[[@CR14]\]. In short, participants eligible for inclusion in this study were men and women from 18 to 79 years old with a diagnosis of metabolic syndrome, hypercholesterolemia, and at moderately high or high risk of CHD. Metabolic syndrome was defined according to the 2005 AHA/National Heart Lung and Blood Institute criteria as having three or more of the following five characteristics; abdominal obesity (waist circumference of ≥102 cm \[≥40 in\] for men or ≥88 cm \[≥35 in\] for women); triglycerides ≥150 mg/dl; HDL-C \<40 mg/dl in men or \<50 mg/dl in women; blood pressure ≥130 mm Hg systolic blood pressure or ≥85 mm Hg diastolic blood pressure or on antihypertensive drug treatment in a subject with a history of hypertension; and fasting glucose ≥100 mg/dl or on drug treatment for elevated glucose \[[@CR1]\]. High-risk subjects with CHD or other forms of atherosclerotic vascular disease (AVD, including peripheral arterial disease, atherosclerotic aortic disease, and carotid artery disease \[[@CR15]\]) were required to have baseline LDL-C levels ≥70 mg/dl. High-risk subjects without AVD (diabetes or multiple risk factors and a 10-year risk level for CHD \>20 %) and moderately high-risk subjects (10-year risk level for CHD of 10 to 20 %) were required to have baseline LDL-C levels ≥100 mg/dl. Eligible subjects who had not received treatment with lipid-lowering agents including over-the-counter dietary supplements of fish oils containing \>1000 mg/day of EPA + DHA, rice yeast extract, Cholestin, bile-acid sequestrants, HMG-CoA reductase inhibitors, ezetimibe, ezetimibe/simvastatin; and niacin (\>200 mg/day) within 6 weeks (8 weeks for fibrates) prior to the first study visit and were at high risk for CHD, or those receiving lipid-lowering therapy who were at moderately high risk for CHD, were randomized to treatment with the recommended starting doses of ezetimibe/simvastatin (10/20 mg) versus atorvastatin (10 and 20 mg) or next higher doses of ezetimibe/simvastatin (10/40 mg) versus atorvastatin (40 mg) for 6 weeks.

Statistical analysis {#Sec5}
--------------------

Consistent with the main study, this *post hoc* subgroup analysis included all randomized subjects with a baseline and at least one post-baseline evaluation. Subgroups included the presence or absence of individual metabolic syndrome factors; abdominal obesity (yes, no), triglycerides ≥ 150 mg/dl (yes, no), HDL-C \< 40 mg/dl for males or \<50 mg/dl for females (yes, no), systolic blood pressure ≥130 mmHg or diastolic blood pressure ≥85 mmHg (yes, no), fasting glucose ≥100 mg/dl (yes, no); and insulin resistance tertiles (estimated using the Homeostasis Model Assessment of Insulin Resistance (HOMA-IR) score \[[@CR16]\]: fasting serum insulin (mU/l) X fasting glucose (mmol/l)/22.5 \[\<2.72, 2.72-4.81, \>4.81\]). Treatment efficacy of ezetimibe/simvastatin 10/20 mg versus atorvastatin 10 mg and 20 mg, and ezetimibe/simvastatin 10/40 mg compared with atorvastatin 40 mg was evaluated within each subgroup using an analysis of variance (ANOVA) model with terms for subgroup, baseline risk stratum, treatment, and treatment by subgroup interaction. Efficacy endpoints included percent change from baseline in LDL-C, HDL-C, non-HDL-C, total cholesterol, VLDL-C, triglycerides, apo B, apo AI, lipid/lipoprotein ratios (total cholesterol:HDL-C, LDL-C:HDL-C, apo B:apo AI, non-HDL-C:HDL-C) and high-sensitivity C-reactive protein (hs-CRP) after 6 weeks of therapy. Least squares mean was determined for LDL-C, HDL-C, non-HDL-C, total cholesterol, VLDL-C, apo B, apo AI, and lipid/lipoprotein ratios, and estimates of between-treatment differences (ezetimibe/simvastatin minus atorvastatin) and corresponding 95 % confidence intervals (CIs) were determined using the ANOVA model. Median values were determined for triglycerides and hs-CRP, and estimates of between-treatment group differences and corresponding 95 % CIs were based on Hodges-Lehmann estimates of shift. Given the large number of comparisons and the post-hoc nature of the analyses, inferential statistics were not conducted in order to avoid issues of multiplicity.

Safety and tolerability were assessed within metabolic syndrome factor and insulin resistance subgroups. Clinical adverse experiences (AEs) were evaluated for all patients who were randomized and received at least one dose of study medication, and included any clinical AE, drug-related AE, serious AE, discontinuations due to an AE, and deaths. Laboratory AEs were evaluated for all subjects who had at least one post-baseline assessment, and included consecutive ≥ 3X the upper limit of normal (ULN) elevations in aspartate aminotransferase and/or alanine aminotransferase, ≥ 10X the ULN increases in creatine kinase with or without muscle symptoms, and a summary by system organ class and specific adverse experience term.

Results {#Sec6}
=======

As reported previously, of the 1,143 subjects randomized to treatment, 658 subjects receiving atorvastatin monotherapy and 438 receiving ezetimibe/simvastatin completed the trial \[[@CR14]\]. Baseline demographics within each metabolic syndrome factor and insulin resistance subgroup were generally similar to those found for the overall study population, \[[@CR14]\] a predominantly white (75 %) and male (56 %) cohort with a mean age of 59 years (Table [1](#Tab1){ref-type="table"}). Over half of the population was obese (body mass index ≥30 kg/m^2^), approximately 50-60 % was diabetic, and one third was classified as high CHD risk subjects with AVD. For each subgroup evaluation, baseline characteristics and lipid values were generally well balanced across the ezetimibe/simvastatin and atorvastatin treatment groups. As expected, baseline values for some parameters varied within a few subgroups due to the association between the parameter being evaluated and the subgroup category (i.e., the percentage of subjects with diabetes was much higher for the subgroup with fasting glucose levels ≥100 mg/dl \[72-74 %\] than for those with levels \<100 mg/dl \[10-11 %\]; baseline triglyceride values were the highest in the subgroup of subjects with triglyceride levels ≥150 mg/dl). Variation in baseline values were noted for some categories (Black, Other) and subgroups (waist circumference \< 40 in \[\<50 in for females\], systolic blood pressure \<130 mmHG \[diastolic blood pressure \<85 mmHg\]) which was due in part to the small number of subjects being evaluated.Table 1Baseline demographics, lipids, lipoproteins, and hs-CRPAbdominal Obesity^a^ males (females)TGHDL-C males (females)SB (DBP)FGHOMA-IR\<40 in(\<35in)≥40 in(≥35in)\<150 mg/dL≥150 mg/dL≥40 mg/dL (≥50 mg/dL)\<40 mg/dL (\<50 mg/dL)\<130 mmHg (\<85 mgHg)≥130 mmHg (≥85 mmHg)\<100 mg/dL≥100 mg/dL\<2.722.72 - 4.81\>4.81All A (N = 94)All E/S (N = 56)All A (N = 586)All E/S (N = 399)All A (N = 212)All E/S (N = 146)All A (N = 474)All E/S (N = 311)All A (N = 287)All E/S (N = 195)All A (N = 399)All E/S (N = 262)All A (N = 56)All E/S (N = 37)All A (N = 630)All E/S (N = 420)All A (N = 196)All E/S (N = 151)All A (N = 490)All E/S (N = 306)All A (N = 232)All E/S (N = 145)All A (N = 225)All E/S (N = 152)All A (N = 218)All E/S (N = 155)Mean Age (SD)59.2 (9.0)62.4 (7.5)58.7 (9.7)59.3 (9.6)60.2 (9.4)60.3 (9.2)58.1 (9.7)59.3 (9.6)60.5 (9.5)60.7 (9.6)57.5 (9.6)58.8 (9.3)53.5 (9.5)51.6 (11.2)59.2 (9.5)60.3 (8.9)59 (10.2)58.8 (8.9)58.7 (9.4)60 (9.7)60 (10.3)60. 9 (8.6)58.5 (8.7)59.9 (9.9)57. 6 (9.7)58.2 (9.5)Female, n(%)24 (25.5)9 (16.1)281 (48.0)180 (45.1)106 (50.0)68 (46.6)201 (42.4)123 (39.5)107 (37.3)66 (33.8)200 (50.1)125 (47.7)31 (55.4)13 (35.1)276 (43.8)178 (42.4)78 (39.8)51 (33.8)229 (46.7)140 (45.8)102 (44.0)57 (39.3)100 (44.4)67 (44.1)100 (45.9)66 (42.6)White, n(%)68 (72.3)37 (66.1)443 (75.6)301 (75.4)157 (74.1)106 (72.6)359 (75.7)234 (75.2)231 (80.5)162 (83.1)285 (71.4)178 (67.9)47 (83.9)26 (70.3)469 (74.4)314 (74.8)129 (65.8)99 (65.6)387 (79.0)241 (78.8)166 (71.6)99 (68.3)164 (72.9)113 (74.3)176 (80.7)124 (80.0)Black, n(%)4 (4.3)4 (7.1)41 (7.0)26 (6.5)21 (9.9)17 (11.6)24 (5.1)13 (4.2)13 (4.5)11 (5.6)32 (8.0)19 (7.3)2 (3.6)1 (2.7)43 (6.8)29 (6.9)17 (8.7)9 (6.0)28 (5.7)21 (6.9)11 (4.7)9 (6.2)21 (9.3)10 (6.6)13 (6.0)11 (7.1)Other, n(%)22 (23.4)15 (26.8)102 (17.4)72 (18.0)34 (16.0)23 (15.8)91 (19.2)64 (20.6)43 (15.0)22 (11.3)82 (20.6)65 (24.8)7 (12.5)10 (27.0)118 (18.7)77 (18.3)50 (25.5)43 (28.5)75 (15.3)44 (14.4)55 (23.7)37 (25.5)40 (17.8)29 (19.1)29 (13.3)20 (12.9)CHD n(%)25 (26.6)17 (30.4)104 (17.7)76 (19.0)46 (21.7)30 (20.5)84 (17.7)63 (20.3)47 (16.4)33 (16.9)83 (20.8)60 (22.9)7 (12.5)5 (13.5)123 (19.5)88 (21.0)52 (26.5)32 (21.2)78 (15.9)61 (19.9)45 (19.4)34 (23.4)44 (19.6)30 (19.7)37 (17.0)28 (18.1)With AVD, n(%)32 (34.0)21 (37.5)162 (27.6)117 (29.3)65 (30.7)44 (30.1)131 (27.6)94 (30.2)80 (27.9)53 (27.2)116 (29.1)85 (32.4)8 (14.3)8 (21.6)188 (29.8)130 (31.0)75 (38.3)48 (31.8)121 (24.7)90 (29.4)66 (28.4)49 (33.8)68 (30.2)44 (28.9)58 (26.6)43 (27.7)BMI ≥ 30 kg/m^2^, n(%)16 (17.2)7 (12.5)387 (66.5)267 (66.9)133 (63.0)89 (61.0)276 (58.7)186 (59.8)164 (57.5)112 (57.4)245 (61.9)163 (62.2)31 (55.4)23 (62.2)378 (60.5)252 (60.0)96 (49.0)80 (53.0)313 (64.5)195 (63.7)91 (39.6)60 (41.4)141 (62.7)102 (67.1)170 (78.3)110 (71.0)Diabetes, n(%)39 (41.5)13 (23.2)339 (57.8)221 (55.4)145 (68.4)96 (65.8)236 (49.8)140 (45.0)159 (55.4)116 (59.5)222 (55.6)120 (45.8)42 (75.0)19 (51.4)339 (53.8)217 (51.7)19 (9.7)16 (10.6)362 (73.9)220 (71.9)89 (38.4)52 (35.9)128 (56.9)80 (52.6)156 (71.6)103 (66.5)Metabolic Syndrome, n(%)70 (74.5)41 (73.2)566 (96.6)387 (97.0)180 (85.3)128 (88.3)461 (97.3)301 (96.8)248 (86.7)171 (87.7)393 (98.5)258 (98.9)48 (85.7)34 (91.9)593 (94.3)395 (94.3)168 (85.7)130 (86.7)473 (96.7)299 (97.7)203 (87.9)124 (86.1)214 (95.1)148 (97.4)213 (97.7)152 (98.1) TG ≥ 150 mg/dL, n(%)73 (77.7)41 (73.2)397 (67.7)269 (67.4)00474 (100)311 (100)176 (61.3)116 (59.5)298 (74.7)195 (74.4)45 (80.4)32 (86.5)429 (68.1)279 (66.4)160 (81.6)122 (80.8)314 (64.1)189 (61.8)156 (67.2)92 (63.4)160 (71.1)105 (69.1)152 (69.7)109 (70.3) Low HDL-C, n(%)58 (61.7)36 (64.3)337 (57.5)224 (56.1)101 (47.6)67 (45.9)298 (62.9)195 (62.7)00399 (100)262 (100)47 (83.9)31 (83.8)352 (55.9)231 (55.0)122 (62.2)101 (66.9)277 (56.5)161 (52.6)122 (52.6)85 (58.6)128 (56.9)88 (57.9)143 (65.6)87 (56.1) Elevated BP, n(%)85 (90.4)53 (94.6)539 (92.0)365 (91.5)201 (94.8)141 (96.6)429 (90.5)279 (89.7)278 (96.9)189 (96.9)352 (88.2)231 (88.2)00630 (100)420 (100)183 (93.4)142 (94.0)447 (91.2)278 (90.8)212 (91.4)134 (92.4)205 (91.1)139 (91.4)204 (93.6)142 (91.6) FG ≥ 100 mg/dL, n(%)55 (58.5)30 (53.6)431 (73.5)275 (68.9)176 (83.0)117 (80.1)314 (66.2)189 (60.8)213 (74.2)145 (74.4)277 (69.4)161 (61.5)43 (76.8)28 (75.7)447 (71.0)278 (66.2)00490 (100)306 (100)124 (53.4)70 (48.3)165 (73.3)102 (67.1)192 (88.1)132 (85.2)LDL-C138.2 (34.5)139.1 (33.1)140.6 (35.7)135.1 (30)131.1 (28.9)133 (29.7)144.4 (37.5)136.6 (30.8)145.7 (34.7)138.5 (31.2)136.4 (35.7)133.2 (29.7)140.6 (39.7)131.9 (24.1)140.2 (35.2)135.7 (30.9)148.2 (35.3)139.7 (29.4)137.1 (35.2)133.4 (30.8)146.7 (35.7)142 (32.6)139 (36.2)134.8 (29.9)135.6 (34.2)130 (28)HDL-C41.5 (9.7)42.5 (12.4)43.3 (10.3)43.2 (10.8)46.3 (11.5)46.8 (12.8)41.6 (9.3)41.3 (9.6)50.3 (10.1)50.7 (11.2)37.8 (6.5)37.6 (6.9)41.4 (8.1)37.3 (8.1)43.2 (10.4)43.6 (11.1)41.9 (10.7)40.4 (10.2)43.5 (10.1)44.4 (11.2)44.2 (11.1)42.9 (10.6)43 (9.3)43.7 (11.2)41.8 (10.1)43 (11.3)non-HDL-C177.4 (40.9)179.8 (35.4)181.1 (40.5)174.6 (35.8)156.9 (30.3)157.9 (31.3)191.3 (40.1)183.2 (35)181.7 (40.7)173.5 (37.4)179.9 (40.5)176.1 (34.6)182.7 (43.4)181.6 (35.6)180.5 (40.3)174.4 (35.8)191.8 (40.8)182.4 (34.5)176.3 (39.7)171.5 (35.9)183 (40.6)178.5 (38)181.3 (41.7)174.8 (33.6)178.1 (40)171.9 (36.1)TG^b^171.5 (97.7)188 (118.6)186 (99.1)177 (101.4)123 (41.4)121 (42.8)215 (93.7)215 (97.7)162 (85.1)157.5 (81.9)200 (106)199.8 (114.9)194 (86.7)217 (141.4)181.5 (100)175 (104.2)201 (105.1)201 (94.9)175.8 (99.1)161.5 (101.4)167.5 (91.2)174 (90.2)183 (109.8)177.5 (122.3)196.3 (99.1)183.5 (109.3)Total C218.9 (42.9)222.3 (39.1)224.3 (41.1)218.1 (36.4)203.2 (33.4)204.8 (32.5)232.8 (41.5)224.9 (37)232 (40.1)224.2 (37.7)217.6 (41.4)214.2 (35.7)223.3 (44.1)218.9 (35)223.6 (41.2)218.4 (37)233.6 (43.3)222.8 (36.1)219.7 (40)216.3 (37)227 (41.3)222.4 (41.2)224.4 (41.9)218.5 (33.2)219.9 (41.6)214.8 (36.1)Apo B134.3 (29.2)137.6 (25.2)137.3 (30.1)133.4 (26.5)121.6 (23.2)122.7 (22.1)143.8 (30.3)138.9 (26.9)136.5 (29.5)131.5 (25.9)137.2 (30.5)135.2 (26.8)141.5 (33.2)138.5 (26.1)136.5 (29.8)133.3 (26.5)144.1 (30.3)139.8 (25.4)134 (29.6)130.7 (26.6)138.2 (29.5)138 (27.8)137.1 (32.3)132.7 (24.7)135.5 (28.8)130.3 (26.5)Apo AI140.4 (24.6)141.5 (27.7)144.8 (24.3)144.8 (25.5)145 (26.3)146.3 (27.9)143.7 (23.6)143.4 (24.6)157.7 (24.8)160.7 (26.2)134.3 (18.8)132.7 (17.9)141 (20.1)136.8 (25.6)144.4 (24.8)145 (25.7)142.1 (26.6)138.4 (24.7)144.9 (23.5)147.2 (25.8)143.6 (26.5)142.3 (24.4)144.7 (22.9)146.3 (25.4)143.9 (23.5)144.5 (27.4)hs-CRP^b^1.8 (2.5)2(3)3.3 (4.6)3.2 (4.7)3 (5.4)2.8 (4.4)3 (4.1)3.1 (4.2)2.7 (3.7)2.4 (3.3)3.3 (4.8)3.5 (5.8)2.3 (2.8)4.2 (4)3 (4.6)2.9 (4.6)2.9 (3.8)2.5 (3.1)3 (4.7)3.5 (5.3)2.3 (3.6)2.3 (3.9)3 (4)3.1 (4)4 (5.3)3.5 (6)Apo = apolipoprotein; All A = data for all atorvastatin doses (10/20/40 mg) combined; Apo = apolipoprotein; BMI = body mass index; BP = blood pressure; All E/S = data for all ezetimibe/simvastatin doses (10/20 mg, 10/40 mg) combined; FG = fasting glucose; HDL-C = high density lipoprotein cholesterol; hsCRP = high-sensitivty C-reactive protein, LDL-C = low density lipoprotein cholesterol, n = number of patients in subgroup (numbers vary slightly between parameters), TG = triglycerides; SD = standard devation ^a^metabolic syndrome defined as ≥3 of the following 5 characteristics; abdominal obesity (waist circumference ≥40 inches (males) or ≥35 inches (females)), TG ≥150 mg/dL, low HDL-C (\<40 mg/dL (males) or \<50 mg/dL (females)), elevated BP (≥130/85 mmHg or on antihypertensive medication or diagnosis of hypertension based on medical history), FG ≥100 mg/dL. ^b^robust SD

Ezetimibe/simvastatin (10/20 mg, 10/40 mg) and atorvastatin (10, 20, 40 mg) therapy produced relatively consistent lipid-altering effects across all metabolic syndrome factor and insulin resistant subgroups, which were similar in magnitude to those previously reported for the overall study population (Fig. [1](#Fig1){ref-type="fig"}) \[[@CR14]\]. All treatments produced significant reductions from baseline in LDL-C, non-HDL-C, total cholesterol, apo B, triglycerides, and lipid/lipoprotein ratios (total cholesterol:HDL-C, LDL-C:HDL-C, apo B:apo AI, non-HDL-C:HDL-C, data not shown) for all subgroups. VLDL-C (data not shown) and hs-CRP changes from baseline were also significant for most subgroup evaluations and consistent with the changes observed for the full cohort. Increases in HDL-C were observed for all subgroups except two (subjects receiving atorvastatin 10 mg and 20 mg with systolic blood pressure \<130 mm Hg \[diastolic \<85 mm Hg\], n = 11 and 21, respectively) and most changes were nominally significant. Elevations in apo AI were smaller in magnitude than HDL-C, and most were not significantly different from baseline (data not shown). When comparing ezetimibe/simvastatin 10/20 mg with atorvastatin 10 mg or 20 mg, and ezetimibe/simvastatin 10/40 mg with atorvastatin 40 mg, treatment with ezetimibe/simvastatin produced generally greater percent reductions from baseline in LDL-C, non-HDL-C, Apo B, total cholesterol, and lipoprotein ratios (data not shown) for all but four subgroup comparisons, with between treatment differences ranging from 0.4 to 27.6 % (Table [2](#Tab2){ref-type="table"}); atorvastatin 40 mg produced greater reductions than ezetimibe/simvastatin 10/40 mg for LDL-C by 2.0 %, LDL-C:HDL-C by 4.5 % and apoB:apoA1 by 1.3 % for subjects with waist circumferences \<40/35 inches, and similar reductions in apoB (0.1 %) for subjects with blood pressure \<130/85 mm Hg. Assessment of the associated 95 % CIs suggest that the lipid-lowering effects of ezetimibe/simvastatin were greater than atorvastatin at the doses compared for most subgroups (Table [2](#Tab2){ref-type="table"}), which is consistent with the significantly greater differences previously reported for the entire cohort (Fig. [1](#Fig1){ref-type="fig"}) \[[@CR14]\]. When compared with atorvastatin, ezetimibe/simvastatin produced numerically larger percent increases in HDL-C and apo AI for all but three subgroups (non-obese, HDL-C ≥40 mg/dl, and HOMA-IR 2.72-4.81 (Table [2](#Tab2){ref-type="table"}). The percent changes from baseline in VLDL-C (not shown), triglycerides, and hs-CRP were similar for the majority of ezetimibe/simvastatin and atorvastatin comparisons and were consistent with the similar treatment effects seen for the overall study.Fig. 1Percent change from baseline in lipid, lipoprotein, and hs-CRP by treatment and metabolic syndrome/IR subgroup. Error bars = standard error. Arrows indicate percent change from baseline reported for the overall study population \[[@CR13]\], with associated value given below the measured parameter for each treatment group. A10/20/40 = atorvastatin 10/20/40 mg; Apo = apolipoprotein; BP = blood pressure \[systolic blood pressure (diastolic blood pressure)\]; E10/S20(40) = ezetimibe 10 mg/simvastatin 20(40) mg; FG = fasting glucose; HDL-C = high density lipoprotein cholesterol; IR = Homeostasis Model Assessment of Insulin Resistance tertiles; hs-CRP = high-sensitivity C-reactive protein, LDL-C = low- density lipoprotein cholesterol; Ob = abdominal obesity (waist circumference ≥40 inches for males or ≥35 inches for females); TG = triglyceridesTable 2Percent differences within metabolic syndrome and insulin resistance subgroups in LDL-C, total cholesterol, HDL-C and triglyceridesAbdominal Obesity^a^TGHDL-CSBP (DBP)FGHOMA-IRNoYes\<150 mg/dL≥150 mg/dL≥40 mg/dL\<40 mg/dL\<130 (85) mmHg≥130 (85) mmHg\<100 mg/dL≥100 mg/dL\<2.722.72-4.81\>4.81n = 20-36n = 177-196n = 62-77n = 142-155n = 82-99n = 119-135n = 11-21n = 194-205n = 52-75n = 144-165n = 57-81n = 68-78(n = 69-79LDL-C, mg/dL (95 % CI) E/S20 - A10^b^−8.6 (−17.3, 0.1)−13.9 (−17.6, −0.3)\*−15.8 (−21.7, −10.0)\*−11.8 (−15.9, −7.7)\*−14.3 (−19.3, −9.2)\*−12.2 (−16.7, −7.8)\*−17.8 (−31.8, −3.8)\*−12.9 (−16.3, −9.4)\*−9.5 (−15.4, −3.6)\*−14.9 (−19.0, −10.9)\*−11.1 (−16.7, −5.4)\*−15.9 (−21.8, −10.0)\*−12.3 (−18.2, −6.5)\* E/S20 - A20^b^−9.1 (−17.8, −0.4)\*−10.4 (−14.1, −6.8)\*−12.0 (−17.7, −6.3)\*−9.3 (−13.4, −5.2)\*−9.1 (−14.1, −4.1)\*−11.1 (−15.6, −6.6)\*−9.8 (−21.8, 2.2)−10.3 (−13.8,-6.8)\*−6.8 (−12.7, −0.9)\*−11.9 (−16.0, −7.9)\*−12.3 (−17.9, −6.7)\*−10.3 (−16.2, −4.4)\*−7.7 (−13.5, −1.8)\* E/S40 - A40^b^2.0 (−8.4, 12.4)−9.3 (−12.8, −5.8)\*−9.8 (−16.0, −3.6)\*−7.2 (−11.2,-3.2)\*−5.90 (−11.3, −0.5)\*−9.2 (−13.4, −4.9)\*−2.4 (−13.5, 8.8)−8.5 (−12.0, −5.0)\*−7.6 (−14.0,-1.1)\*−8.0 (−11.9,-4.1)\*−8.1 (−14.2, −2.0)\*−8.9 (−14.5, −3.2)\*−7.1 (−12.9, −1.4)\*TC, mg/dL (95 % CI) E/S20 - A10^b^−4.8 (−11.2, 1.5)−7.7 (−10.3, −5.1)\*−10.2 (−14.4, −5.9)\*−5.8 (−8.8, −2.9)\*−7.6 (−11.2, −3.9)\*−7.0 (−10.2, −3.8)\*−10.6 (−20.8, −0.5)\*−7.0 (−9.5, −4.5)\*−4.3 (−8.5, 0.0)−8.7 (−11.6, −5.7)\*−6.1 (−10.2, −2.0)\*−8.4 (−12.6, −4.1)\*−7.1 (−11.4, −2.9)\* E/S20 - A20^b^−4.8 (−11.0, 1.5)−5.5 (−8.1, −2.8)\*−7.1 (−11.2, −3.0)\*−4.4 (−7.4, −1.4)\*−4.6 (−8.2,-1.0)\*−6.0 (−9.2, −2.7)\*−4.6 (−13.3, 4.2)−5.5 (−8.0, −2.9)\*−2.8 (−7.1, 1.5)−6.6 (−9.6, −3.7)\*−7.4 (−11.4, −3.3)\*−4.8 (−9.1, −0.5)\*−3.7 (−8.0, 0.6) E/S40 - A40^b^−3.0 (−10.6, 4.6)−4.8 (−7.3, −2.2)\*−4.3 (−8.8, 0.2)−4.5 (−7.4, −1.6)\*−3.1 (−7.0, 0.9)−5.3 (−8.4, −2.2)\*−1.0 (−9.0, 7.0)−4.8 (−7.3, −2.2)\*−4.9 (−9.6, −0.2)\*−4.1 (−7.0, −1.3)\*−5.8 (−10.2,-1.3)\*−4.8 (−8.9, −0.6)\*−2.6 (−6.8, 1.5)HDL-C, mg/dL (95 % CI) E/S20 - A10^b^2.4 (−4.5, 9.3)3.3 (0.4, 6.2)\*3.9 (−0.7, 8.5)3.2 (0.0, 6.5)1.3 (−2.6, 5.3)5.0 (1.4, 8.5)\*9.8 (−1.3, 20.8)3.0 (0.3, 5.7)\*3.2 (−1.4, 7.8)3.4 (0.2, 6.6)\*4.2 (−0.2, 8.7)4.1 (−0.5, 8.8)1.4 (−3.2, 6.0) E/S20 -A20^b^−0.2 (−7.0, 6.7)1.6 (−1.3, 4.5)2.0 (−2.5, 6.5)0.8 (−2.5, 4.0)0.0 (−3.9, 3.9)2.2 (−1.4, 5.7)8.9 (−0.6, 18.4)0.4 (−2.3, 3.2)0.8 (−3.9, 5.4)1.3 (−1.9, 4.5)3.0 (−1.4, 7.4)−0.3 (−5.0, 4.4)0.2 (−4.4, 4.9) E/S40 - A40^b^−2.8 (−11.0, 5.5)4.7 (1.9, 7.5)\*5.0 (0.1, 9.9)\*3.6 (0.5, 6.7)\*4.3 (0.1, 8.6)\*3.7 (0.4, 7.1)\*9.1 (0.3, 17.9)\*3.5 (0.7, 6.2)\*4.8 (−0.3, 9.9)3.2 (0.1, 6.3)\*5.6 (0.8, 10.5)\*4.9 (0.4, 9.4)\*1.1 (−3.5, 5.6)TG, mg/dL (95 % CI) E/S20 - A10^b^−7.4 (−20.3, 6.4)0.1 (−4.7, 4.6)−0.9 (−9.0, 6.2)−1.5 (−6.8, 3.5)1.8 (−5.2, 8.3)−3.1 (−9.1, 2.4)−2.7 (−20.8, 11.1)−0.8 (−5.4, 3.6)−0.3 (−7.9, 7.7)−1.3 (−6.8, 3.9)−3.9 (−11.7, 3.9)1.4 (−6.1, 8.8)−0.3 (−8.1, 6.9) E/S20 - A20^b^−0.8 (−12.9, 11.5)3.5 (−1.3, 8.2)7.3 (−0.2, 14.8)0.3 (−5.0, 5.7)4.3 (−2.3, 11.1)1.7 (−4.1, 7.3)2.1 (−11.1, 16.2)2.9 (−1.7, 7.5)2.4 (−4.7, 10.8)2.7 (−2.5, 8.3)−0.1 (−8.0, 8.2)4.2 (−3.5, 12.2)3.6 (−4.0, 10.5) E/S40 - A40^b^−0.3 (−19.6, 15.4)−0.4 (−4.9, 4.1)2.2 (−6.6, 10.9)−1.4 (−6.4, 3.5)−1.6 (−8.8, 5.1)0.4 (−5.3, 5.8)−2.7 (−18.5, 11.5)−0.1 (−4.7, 4.5)−6.1 (−13.9, 2.6)1.9 (−3.4, 6.9)−4.0 (−12.7, 4.9)−1.2 (−8.2, 5.7)4.8 (−3.3, 12.3)A10/20/40 = atorvastatin 10/20/40 mg; E = ezetimibe 10 mg; FG = fasting glucose; HDL-C = high density lipoprotein cholesterol; HOMA-IR = Homeostasis Model Assessment of Insulin Resistance; LDL-C = low density lipoprotein cholesterol, n = number of patients in subgroup (some numbers vary slightly between parameters), S20/40 = simvastatin 20/40 mg; SBP (DBP) = systolic blood pressure (diastolic blood pressure); SD = standard deviation; TG = triglycerides\*Confidence intervals of difference parameters do not contain 0 ^a^abdominal obesity = waist circumference ≥40 inches for males or ≥35 inches for females ^b^between-treatment differences (E+S minus A) based on ANOVA model with terms for subgroup (baseline abdominal obesity, TG, HDL-C, blood pressure, fasting glucose, and HOMA-IR, based on subgroup being analyzed), baseline stratum, treatment group, and the interaction of treatment group and subgroup Values in parentheses = 95% confidence intervals

All doses of ezetimibe/simvastatin and atorvastatin were generally safe and well tolerated, with an incidence of one or more adverse experiences (11.3 to 23.2 %), drug-related adverse experiences (1.4 to 5.7 %), and serious adverse experiences (0 to 1.8 %) that was generally similar across all subgroups (Table [3](#Tab3){ref-type="table"}) and consistent with the primary study results \[[@CR14]\]. The statistical significance of differences between subgroups and between treatments within each subgroup was not evaluated due to the *post hoc* nature of these analyses.Table 3Adverse experience summary of pooled treatment groupsAdverse ExperienceObesityTGHDL-CSB/ DBPFGHOMA-IRmales/femalesmales/femalesn (%)\<40 in/\<35in)≥40 in/≥35in)\<150 mg/dL≥150 mg/dL≥40 mg/dL/ ≥50 mg/dL\<40 mg/dL/ \<50 mg/dL\<130 mmHg/ \<85 mgHg≥130 mmHg/ ≥ 85 mmHg\<100 mg/dL≥100 mg/dL\<2.722.72 - 4.81\>4.81All AE/All SAll AE/All SAll AE/All SAll AE/All SAll AE/All SAll AE/All SAll AE/All SAll AE/All SAll AE/All SAll AE/All SAll AE/All SAll AE/All SAll AE/All Sn = 94n = 56n = 578n = 392n = 209n = 144n = 469n = 306n = 282n = 190n = 396n = 260n = 56n = 36n = 622n = 414n = 192n = 147n = 486n = 303n = 229n = 142n = 222n = 151n = 218n = 154With one or more AE14 (14.9)12 (21.4)120 (20.8)64 (16.3)40 (19.1)21 (14.6)94 (20.0)55 (18.0)57 (20.2)35 (18.4)77 (19.4)41 (15.8)8 (14.3)6 (16.7)126 (20.3)70 (16.9)39 (20.3)26 (17.7)95 (19.5)50 (16.5)47 (20.5)33 (23.2)43 (19.4)17 (11.3)40 (18.3)26 (16.9)With drug-related AE^a^2 (2.1)2 (3.6)24 (4.2)13 (3.3)3 (1.4)4 (2.8)23 (4.9)11 (3.6)11 (3.9)7 (3.7)15 (3.8)8 (3.1)2 (3.6)1 (2.8)24 (3.9)14 (3.4)11 (5.7)5 (3.4)15 (3.1)10 (3.3)4 (1.7)5 (3.5)10 (4.5)3 .0 (2.0)11 (5.0)7 (4.5)With serious AE1 (1.1)0 (0)8 (1.4)1 (0.3)2 (1.0)1 (0.7)7 (1.5)0 (0)4 (1.4)0 (0)5 (1.3)1 (0.4)1 (1.8)0 (0)8 (1.3)1 (0.2)3 (1.6)1 (0.7)6 (1.2)0 (0)3 (1.3)0 (0)3 (1.4)1 (0.7)2 (0.9)0 (0)With serious drug-related AE0 (0)0 (0)1 (0.2)0 (0)0 (0)0 (0)1 (0.2)0 (0)1 (0.4)0 (0)0 (0)0 (0)0 (0)0 (0)1 (0.2)0 (0)0 (0)0 (0)1 (0.2)0 (0)0 (0)0 (0)1 (0.5)0 (0)0 (0)0 (0)Discontinued due to AE1 (1.1)0 (0)11 (1.9)6 (1.5)1 (0.5)2 (1.4)11 (2.3)4 (1.3)4 (1.4)3 (1.6)8 (2.0)3 (1.2)1 (1.8)0 (0)11 (1.8)6 (1.4)3 (1.6)1 (0.7)9 (1.9)5 (1.7)2 (0.9)1 (0.7)4 (1.8)1 (0.7)4 (1.8)4 (2.6)drug-related0 (0)0 (0)7 (1.2)4 (1.0)0 (0)1 (0.7)7 (1.5)3 (1.0)2 (0.7)3 (1.6)5 (1.3)1 (0.4)1 (1.8)0 (0)6 (1.0)4 (1.0)2 (1.0)1 (0.7)5 (1.0)3 (1.1)1 (0.4)0 (0)2 (0.9)1 (0.7)3 (1.4)3 (1.9)serious0 (0)0 (0)2 (0.3)0 (0)0 (0)0 (0)2 (0.4)0 (0)2 (0.7)0 (0)0 (0)0 (0)0 (0)0 (0)2 (0.3)0 (0)0 (0)0 (0)2 (0.4)0 (0)0 (0)0 (0)1 (0.5)0 (0)1 (0.5)0 (0)serious drug-related0 (0)0 (0)1 (0.2)0 (0)0 (0)0 (0)1 (0.2)0 (0)1 (0.4)0 (0)0 (0)0 (0)0 (0)0 (0)1 (0.2)0 (0)0 (0)0 (0)1 (0.2)0 (0)0 (0)0 (0)1 (0.5)0 (0)0 (0)0 (0)Deaths0 (0)0 (0)0 (0)0 (0)0 (0)0 (0)0 (0)0 (0)0 (0)0 (0)0 (0)0 (0)0 (0)0 (0)0 (0)0 (0)0 (0)0 (0)0 (0)0 (0)0 (0)0 (0)0 (0)0 (0)0 (0)0 (0)Pre-specified^b^ m/n (%)ALT or AST ≥ 3xULN, consecutive^c^0/921/55 (1.8)2/559 (0.4)5/385 (1.3)0/2031/142 (0.7)2/454 (0.4)5/300 (1.7)2/273 (0.7)5/186 (2.7)0/3841/256 (0.4)0/531/35 (2.9)2/604 (0.3)5/407 (1.2)1/188 (0.5)2/143 (1.4)1/469 (0.2)4/299 (1.3)0/2223/141 (2.1)2/216 (0.9)1/147 0.7)0/2112/151 (1.3)ALT ≥ 3xULN, consecutive^c^0/920/552/558 (0.4)1/385 (0.3)0/2030/1422/453 (0.4)1/300 (0.3)2/272 (0.7)0/1860/3841/256 (0.4)0/530/352/603 (0.3)1/407 (0.2)1/188 (0.5)1/143 (0.7)1/468 ( 0.2)0/2990/2221/141 (0.7)2/216 (0.9)0/1470/2100/151AST ≥ 3xULN, consecutive^c^0/921/55 (1.8)1/559 (0.2)4/385 (1.0)0/2031/142 (0.7)1/454 (0.2)4/300 (1.3)1/273 (0.4)5/186 (2.7)0/3840/2560/531/35 (2.9)1/604 (0.2)4/407 (1.0)0/1881/143 (0.7)1/469 (0.2)4/299 (1.3)0/2222/141 (1.4)1/216 (0.5)1/147 (0.7)0/2112/151 (1.3)CK ≥ 10xULN0/921/55 (1.8)0/5590/3850/2030/1420/4541/300 (0.3)0/2731/186 (0.5)0/3840/2560/530/350/6041/407 (0.2)0/1881/143 (0.7)0/4690/2990/2221/141 (0.7)0/2160/1470/2110/151CK ≥ 10xULN with muscle symptoms0/920/550/5590/3850/2030/1420/4540/3000/2730/1860/3840/2560/530/350/6040/4070/1880/1430/4690/2990/2220/1410/2160/1470/2110/151CK ≥ 10xULN with drug-related muscle symptoms0/920/550/5590/3850/2030/1420/4540/3000/2730/1860/3840/2560/530/350/6040/4070/1880/1430/4690/2990/2220/1410/2160/1470/2110/151Hepatitis-related AEs0/940/560/5780/3920/2090/1440/4690/3060/2820/1900/3960/2600/560/360/6220/4140/1920/1470/4860/3030/2290/1420/2220/1510/2180/154Gallbladder-related AEs0/940/561/578 ( 0.2)0/3920/2090/1441/469 ( 0.2)0/3061/282 (0.4)0/1900/3960/2600/560/361/622 (0.2)0/4140/1920/1471/486 (0.2)0/3030/2290/1421/222 (0.5)0/1510/2180/154Gastrointestinal-related AEs4/94 (4.3)4/56 (7.1)24/578 (4.2)21/392 (5.4)8/209 (3.8)8/144 (5.6)20/469 (4.3)17/306 (5.6)10/282 (3.5)14/190 (7.4)18/396 (4.5)11/260 (4.2)1/56 (1.8)1/36 (2.8)27/622 (4.3)24/414 (5.8)10/192 (5.2)11/147 (7.5)18/486 (3.7)14/303 ( 4.6)10/229 (4.4)12/142 (8.5)12/222 (5.4)5/151 (3.3)6/218 (2.8)8/154 (5.2)Allergic reaction or rash AEs1/94 (1.1)1/56 (1.8)5/578 (0.9)4/392 (1.0)2/209 (1.0)1/144 (0.7)4/469 (0.9)4/306 (1.3)2/282 (0.7)5/190 (2.6)4/396 (1.0)0/2600/560/566/622 (1.0)5/414 (1.2)3/192 (1.6)0/1473/486 (0.6)5/303 (1.7)1/229 (0.4)1/142 (0.7)2/222 (0.9)2/151 (1.3)3/218 (1.4)2/154 (1.3)Although a patient may have had two or more clinical adverse experiences the patient is counted only once in a category. The same patient may appear in different categoriesE = Ezetimibe 10 mg; All Atorva = Atorvastatin(10,20,40 mg) pooled across all doses; E/All Simva = Ezetimibe/Simvastatin(10/20, 10/40 mg) pooled across all doses; n = Number of randomized and treated patients in each treatment group^a^Determined by the investigator to be possibly, probably, or definitely related to the drug^b^For laboratory safety (ALT, AST, CK), patients must have taken at least one dose of study medication and have at least one postbaseline measurement within 14 days of the last dose of study therapy to be included in the analysis% = m/n x 100 = (number of patients within the Tier 1 adverse event category / number of treated patients \[with one or more laboratory tests postbaseline, if parameter is a laboratory parameter\]) × 100^c^This category includes those patients with (a) two consecutive measurements ≥3xULN, (b) a single, last measurement ≥3xULN, or (c) a measurement ≥3xULN followed by a measurement \<3xULN that was taken more than 2 days after the last dose of study medication

Discussion {#Sec7}
==========

This *post hoc* study of subjects with hypercholesterolemia, metabolic syndrome, and moderately high or high CHD risk was designed to evaluate the effect of individual metabolic syndrome factors and insulin resistance on the lipid-lowering efficacy of ezetimibe/simvastatin (10/20 mg, 10/40 mg) and atorvastatin (10, 20, 40 mg). Results showed a consistent treatment effect for both ezetimibe/simvastatin and atorvastatin when comparing subjects with to those without the individual metabolic syndrome factors of abdominal obesity (based on waist circumference), elevated triglycerides, low HDL-C, high blood pressure, and fasting glucose ≥100 mg/dl; or within low, middle, or high tertile subgroups of insulin resistance as measured by HOMA-IR. The magnitude of lipid-altering effects produced by each treatment regimen was generally similar across all subgroups, suggesting that ezetimibe/simvastatin and atorvastatin treatment effects are not substantively influenced by these factors. Ezetimibe/simvastatin produced greater percent reductions in LDL-C, non-HDL-C, apo B, total cholesterol, and lipid/lipoprotein ratios than atorvastatin for most subgroups and dose comparisons. These effects were similar to the results reported for the overall study cohort \[[@CR14]\] and consistent with three other studies designed to evaluate ezetimibe/simvastatin and atorvastatin efficacy in subjects at moderately high or high CHD risk with hypercholesterolemia (VYVA) \[[@CR17]\], with diabetes mellitus and hypercholesterolemia (VYTAL) \[[@CR18]\], or with advanced age (≥65 years) and hypercholesterolemia (VYTELD) \[[@CR19]\]. In addition, a *post hoc* multivariate analysis demonstrated that ezetimibe/simvastatin treatment was consistently more effective than atorvastatin treatment in at-risk patients with the MetS in patients ≥65 years, in those with abdominal obesity, and with lower baseline hs-CRP at the specified dose comparisons (VYMET) \[[@CR20]\].

The altered regulation of lipid metabolism found in patients with metabolic syndrome, including low HDL-C, high triglycerides, and elevated concentrations of small-dense LDL (sdLDL) particles, seems to play a major role in elevating cardiovascular disease risk \[[@CR13]\]. In patients with metabolic syndrome, high triglyceride content in the liver is associated with the increased hepatic secretion of triglyceride-rich VLDL. Cholesteryl ester transfer protein (CETP) mediates the exchange of cholesteryl ester for triglyceride between triglyceride-rich lipoproteins and HDL, resulting in HDL with increased susceptibility to hepatic lipase, generation of smaller HDL particles, and accelerated HDL catabolism. A similar CETP-mediated process is responsible for the formation of sdLDL; however, these particles have a slower catabolic rate and increased atherogenicity \[[@CR21]\]. Atorvastatin has been shown to produce a dose-dependent reduction in sdLDL with a concomitant shift from the more atherogenic small-dense to larger, less dense LDL particles for subjects with hypertriglyceridemia \[[@CR22]\] and other forms of dyslipidemia \[[@CR23]\]. Ezetimibe alone or in combination with statins has also been shown to reduce levels of sdLDL \[[@CR24]--[@CR26]\]. While lipid-lowering therapy has a demonstrated effect on lowering sdLDL, effects of individual metabolic syndrome factors or insulin resistance on sdLDL kinetics during treatment are unknown and require further investigation.

As seen for the overall study, all treatments were generally well tolerated and clinical adverse experiences were similar across all metabolic syndrome factor and insulin resistance subgroups. Because the subgroup sizes were relatively small and the event rates were low overall, it is difficult to generalize these results for subgroups of patients with individual components of the metabolic syndrome or insulin resistance.

As a *post hoc* analysis, results from this study have several limitations and should be interpreted with appropriate caution. Since many of the subgroups were limited in size when compared with the entire cohort and multiple comparisons were made, results may not truly be representative of a given subpopulation. This study was also not designed to have adequate power to determine the statistical significance for between-treatment differences in subgroups. These findings, however, are consistent with several prior studies showing the greater lipid-lowering efficacy of ezetimibe/simvastatin therapy versus statin monotherapy in patients with diabetes or metabolic syndrome \[[@CR27]--[@CR30]\]. The short duration of this study precludes evaluation of long-term treatment efficacy or safety.

In summary, results from this study suggest that ezetimibe/simvastatin and atorvastatin efficacy is generally well maintained across metabolic syndrome factor and insulin resistance subgroups. Ezetimibe/simvastatin provided greater lipid-altering benefits for most key parameters than atorvastatin at the doses compared, which may be of interest to clinicians when evaluating treatment options for patients with metabolic syndrome and moderately high to high CHD risk. Additional studies will be needed to determine the final clinical significance of these results.
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